ALEC

Alector's stock price declined by 36.82% from $2.96 on September 30, 2025, to $1.87 on September 29, 2026, with a 1-year change of -33.8% as of October 9, 2026. In October 2026, shares surged approximately 22% following the announcement of an exclusive global licensing agreement with Genentech for its AL050 program, which included a $100 million upfront payment and potential milestone payments up to $1.17 billion. In September 2026, a co-founder sold approximately $193k worth of stock, contributing to total insider sales of $295,633.00 over the past three months, which exceeded insider purchases. In August 2026, Alector's shares climbed roughly 70% over 30 days due to a better-than-expected second-quarter earnings report, showing a narrower loss per share and revenue surpassing analyst forecasts, leading to a 60% increase in consensus revenue estimates for fiscal year 2026. In May 2026, the stock experienced a significant daily drop of 13.93%. From March to June 2026, several insider sales were reported by the Principal Accounting Officer, CEO, and CFO. In the month leading up to October 5, 2026, one analyst upgraded Alector's stock with no downgrades, and consensus revenue estimates for fiscal year 2026 increased by 112% in October 2026.